DK0868519T3 - Diagnose og behandling af AUR-1- og/eller AUR-2-relaterede lidelser - Google Patents

Diagnose og behandling af AUR-1- og/eller AUR-2-relaterede lidelser

Info

Publication number
DK0868519T3
DK0868519T3 DK96940870T DK96940870T DK0868519T3 DK 0868519 T3 DK0868519 T3 DK 0868519T3 DK 96940870 T DK96940870 T DK 96940870T DK 96940870 T DK96940870 T DK 96940870T DK 0868519 T3 DK0868519 T3 DK 0868519T3
Authority
DK
Denmark
Prior art keywords
aur
polypeptides
diagnosis
treatment
related disorders
Prior art date
Application number
DK96940870T
Other languages
Danish (da)
English (en)
Inventor
Gregory D Plowman
Kevin G Mossie
Original Assignee
Sugen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26678652&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK0868519(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sugen Inc filed Critical Sugen Inc
Application granted granted Critical
Publication of DK0868519T3 publication Critical patent/DK0868519T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52—Genes encoding for enzymes or proenzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/027—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a retrovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plant Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Steroid Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DK96940870T 1995-12-18 1996-11-25 Diagnose og behandling af AUR-1- og/eller AUR-2-relaterede lidelser DK0868519T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US880995P 1995-12-18 1995-12-18
US2394396P 1996-08-14 1996-08-14

Publications (1)

Publication Number Publication Date
DK0868519T3 true DK0868519T3 (da) 2006-05-08

Family

ID=26678652

Family Applications (1)

Application Number Title Priority Date Filing Date
DK96940870T DK0868519T3 (da) 1995-12-18 1996-11-25 Diagnose og behandling af AUR-1- og/eller AUR-2-relaterede lidelser

Country Status (15)

Country Link
US (2) US5962312A (ja)
EP (2) EP0868519B1 (ja)
JP (1) JP3944241B2 (ja)
KR (1) KR100459052B1 (ja)
AT (1) ATE315654T1 (ja)
AU (1) AU716330B2 (ja)
CA (1) CA2239692C (ja)
DE (1) DE69635740T2 (ja)
DK (1) DK0868519T3 (ja)
ES (1) ES2255715T3 (ja)
IL (1) IL124728A (ja)
NO (1) NO323646B1 (ja)
NZ (1) NZ323795A (ja)
PT (1) PT868519E (ja)
WO (1) WO1997022702A1 (ja)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6716575B2 (en) * 1995-12-18 2004-04-06 Sugen, Inc. Diagnosis and treatment of AUR1 and/or AUR2 related disorders
EP1004667B1 (en) * 1997-08-15 2006-10-18 Hiroshima University Cell cycle-regulating proteins
US5962232A (en) * 1998-01-30 1999-10-05 Incyte Pharmaceuticals, Inc. Protein kinase molecules
WO2001021596A1 (en) * 1999-09-21 2001-03-29 Astrazeneca Ab Quinazoline derivatives and their use as pharmaceuticals
US6352858B1 (en) 2000-09-11 2002-03-05 Isis Pharmaceuticals, Inc. Antisense modulation of BTAK expression
JP2002236125A (ja) * 2001-02-06 2002-08-23 Igaku Seibutsugaku Kenkyusho:Kk タンパク質リン酸化酵素活性の測定方法、測定用キット及び測定に用いる抗体
US6872533B2 (en) 2001-07-27 2005-03-29 The Regents Of The University Of California STK15 (STK6) gene polymorphism and methods of determining cancer risk
US20050216961A1 (en) * 2002-03-28 2005-09-29 Delaney Allen D Cancer associated protein kinases and their uses
FR2840905B1 (fr) * 2002-06-12 2006-07-07 Centre Nat Rech Scient Anticorps monoclonal anti-aurora-a, son procede d'obtention, et ses utilisations dans le diagnostic et le traitement des cancers
US7444273B1 (en) * 2002-06-21 2008-10-28 Takeda San Diego, Inc. Crystallization of aurora/LPL1P-related kinase
US20120045390A1 (en) * 2002-09-11 2012-02-23 Genentech, Inc. Composition and Methods for the Diagnosis and Treatment of Tumor
EP1570080A4 (en) 2002-11-15 2006-03-01 Genomic Health Inc GENE EXPRESSION PROFILING OF EGFR-POSITIVE CANCER DISEASE
MY136174A (en) 2002-12-24 2008-08-29 Astrazeneca Ab Phosphonooxy quinazoline derivatives and their pharmaceutical use
US20040231909A1 (en) 2003-01-15 2004-11-25 Tai-Yang Luh Motorized vehicle having forward and backward differential structure
JP2006521793A (ja) * 2003-02-06 2006-09-28 ゲノミック ヘルス， インコーポレイテッド Ｅｇｆｒインヒビター薬物に応答性の遺伝子発現マーカー
EP1597391B1 (en) * 2003-02-20 2008-10-29 Genomic Health, Inc. Use of intronic rna to measure gene expression
US20050164218A1 (en) * 2003-05-30 2005-07-28 David Agus Gene expression markers for response to EGFR inhibitor drugs
EP3170906B1 (en) * 2003-06-24 2018-08-22 Genomic Health, Inc. Prediction of likelihood of cancer recurrence
WO2005008213A2 (en) * 2003-07-10 2005-01-27 Genomic Health, Inc. Expression profile algorithm and test for cancer prognosis
JP2007509613A (ja) * 2003-10-16 2007-04-19 ジェノミック ヘルス， インコーポレイテッド 遺伝子発現プロファイリングのためのｑＲＴ−ＰＣＲアッセイシステム
JP2007514759A (ja) 2003-12-19 2007-06-07 タケダ サン ディエゴ インコーポレイテッド キナーゼ阻害剤
WO2005064019A2 (en) * 2003-12-23 2005-07-14 Genomic Health, Inc. Universal amplification of fragmented rna
CA2563074C (en) * 2004-04-09 2014-05-20 Genomic Health, Inc. Gene expression markers for predicting response to chemotherapy
JP4812763B2 (ja) * 2004-05-18 2011-11-09 ライジェル ファーマシューティカルズ， インコーポレイテッド シクロアルキル置換ピリミジンジアミン化合物およびそれらの用途
US20050282208A1 (en) * 2004-06-18 2005-12-22 Cytokinetics, Inc. Cellular phenotype
JP2008510734A (ja) 2004-08-18 2008-04-10 タケダ サン ディエゴ インコーポレイテッド キナーゼ阻害剤
US7285569B2 (en) 2004-09-24 2007-10-23 Hoff Hoffmann-La Roche Inc. Tricycles, their manufacture and use as pharmaceutical agents
TW200624431A (en) 2004-09-24 2006-07-16 Hoffmann La Roche Phthalazinone derivatives, their manufacture and use as pharmaceutical agents
EP1812439B2 (en) 2004-10-15 2017-12-06 Takeda Pharmaceutical Company Limited Kinase inhibitors
PL1836629T3 (pl) * 2004-11-05 2020-06-15 Genomic Health, Inc. Przewidywanie odpowiedzi na chemioterapię z zastosowaniem markerów ekspresji genu
ATE550440T1 (de) * 2004-11-05 2012-04-15 Genomic Health Inc Molekulare indikatoren für brustkrebsprognose und vorhersage des ansprechens auf eine behandlung
GB2420559B (en) * 2004-11-15 2008-08-06 Rigel Pharmaceuticals Inc Stereoisomerically enriched 3-aminocarbonyl bicycloheptene pyrimidinediamine compounds and their uses
KR20070113286A (ko) 2005-04-14 2007-11-28 에프. 호프만-라 로슈 아게 아미노피라졸 유도체, 이의 제조 및 약학 제제로서의 용도
US20070082327A1 (en) * 2005-09-09 2007-04-12 Cytokinetics, Inc. A Delaware Corporation Cellular phenotype
US8119655B2 (en) 2005-10-07 2012-02-21 Takeda Pharmaceutical Company Limited Kinase inhibitors
WO2007079445A2 (en) * 2006-01-03 2007-07-12 Sunesis Pharmaceuticals, Inc. Aurora expression constructs
JP2010505962A (ja) 2006-10-09 2010-02-25 武田薬品工業株式会社 キナーゼ阻害剤
JP5279063B2 (ja) * 2007-05-25 2013-09-04 国立大学法人愛媛大学 Ｈｌａ−ａ２拘束性抗原ペプチドおよびその用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4945050A (en) * 1984-11-13 1990-07-31 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues and apparatus therefor
US5283173A (en) * 1990-01-24 1994-02-01 The Research Foundation Of State University Of New York System to detect protein-protein interactions
DE69232718T2 (de) * 1991-02-22 2003-04-03 American Cyanamid Co Identifizierung eines menschlichen rezeptor-tyrosinkinasegens
WO1994023039A1 (en) * 1993-04-07 1994-10-13 The Institute Of Cancer Research: Royal Cancer Hospital Methods for screening of substances for therapeutic activity and yeast for use therein
US5830648A (en) * 1995-05-05 1998-11-03 Sugen, Inc. Assay and method for transcript imaging

Also Published As

Publication number Publication date
CA2239692A1 (en) 1997-06-26
US5972676A (en) 1999-10-26
WO1997022702A1 (en) 1997-06-26
PT868519E (pt) 2006-05-31
DE69635740D1 (de) 2006-04-06
IL124728A (en) 2007-06-03
ATE315654T1 (de) 2006-02-15
NO982794D0 (no) 1998-06-17
KR20000064437A (ko) 2000-11-06
NO323646B1 (no) 2007-06-18
IL124728A0 (en) 1999-01-26
AU716330B2 (en) 2000-02-24
ES2255715T3 (es) 2006-07-01
KR100459052B1 (ko) 2005-01-15
CA2239692C (en) 2008-12-16
JP2000502895A (ja) 2000-03-14
EP0868519B1 (en) 2006-01-11
EP1655369A1 (en) 2006-05-10
EP0868519A1 (en) 1998-10-07
NO982794L (no) 1998-08-18
NZ323795A (en) 2000-01-28
JP3944241B2 (ja) 2007-07-11
US5962312A (en) 1999-10-05
AU1082697A (en) 1997-07-14
DE69635740T2 (de) 2006-09-14

Similar Documents

Publication Publication Date Title
DK0868519T3 (da) Diagnose og behandling af AUR-1- og/eller AUR-2-relaterede lidelser
DK1051500T3 (da) Diagnose og behandling af AUR1- og/eller AUR2-relaterede sygdomme
DE69117949D1 (de) Mit akuter pankreatitis assoziiertes protein, mittel zur diagnose von akuter pankreatitis
ATE177147T1 (de) Säugetier-rezeptoren für interleukin 10 (il-10)
ATE516304T1 (de) Nrg-2 nukleinsäuren, polypeptide und diagnostische / therapeutische methoden
CY1111950T1 (el) 32 ανθρωπινες εκκρινομενες πρωτεϊνες
WO1997048723A3 (en) Ptp-20, pcp-2, bdp1, clk and sirp proteins and related products
DK0948604T3 (da) Screeningsmetoder for forbindelser som binder til PYK2-polypeptidet
ATE438657T1 (de) Charakterisierung von granulozytischer ehrlichia und methoden für ihre verwendung.
ATE245699T1 (de) Rekombinant pgp3, verfahren zu dessen herstellung,und dessen verwendung in der diagnose und therapie
DE69935220D1 (de) Von menschlichem tumor stammendes polypeptidhormon phosphatonin
DE68925275D1 (de) Endotoxin-bindeprotein und dessen verwendung
WO1999033870A3 (en) Human regulatory proteins
DE3751893D1 (de) Polypeptid und dessen Herstellung
ATE265533T1 (de) Saeugetierchemokine
DE69734890D1 (de) Rdgb-proteine
DE3750240D1 (de) Gen, das ein Insektizid-Protein kodiert, und Herstellung des Proteins durch Verwendung dieses Gens.
WO1996037610A3 (en) Cck-4, a receptor tyrosine kinase, and methods for diagnosis and treatment of cck-4 signal transduction disorders
ATE124722T1 (de) Für das plazentaprotein 9 (pp9) kodierende cdna, ihre isolierung und verwendung.
ATE542900T1 (de) Icbp90-polypeptide, polypeptidfragmente davon, die dafür kodierenden polynukleotide, und ihre verwendung zur behandlung und diagnose von krebs